Is Onto Innovation (ONTO) Still Worth A Premium On Strong Growth Forecasts?

Onto Innovation

Onto Innovation

ONTO

0.00

Recent analyst forecasts for Onto Innovation (ONTO) center on its upcoming earnings report, with expectations for quarterly earnings of $1.68 per share and revenue of $325.6 million. These projections highlight anticipated year over year growth across multiple business lines, based on analyst estimates.

Onto Innovation’s share price has been volatile in recent months, with a 7.12% 1 day share price return and 18.90% 7 day share price return, yet a 6.50% decline over 30 days. Even so, the year to date share price return of 73.39% and 1 year total shareholder return of 203.54% point to strong momentum supported by a 3 year total shareholder return of 139.17%.

If the recent swing in Onto Innovation has you thinking about where else sentiment is building around chip related infrastructure, this is a good moment to scan 55 AI infrastructure stocks.

After a surge that left Onto Innovation up strongly over 1 year yet softer over the past month, the question now is whether the current price still leaves enough upside to justify the risk as earnings approach.

Most Popular Narrative: 24.3% Undervalued

Onto Innovation last closed at $287.60, while the most followed narrative on the stock anchors fair value at $380. This gap is where the bullish story starts to build for many investors following the company.

Onto Innovation is emerging as one of the most strategically important semiconductor equipment companies in the AI supply chain. While much investor attention remains focused on GPU manufacturers and memory suppliers, the next bottleneck increasingly lies in advanced packaging, the complex process of stacking, connecting, and inspecting AI chips and HBM memory at nanometer precision.

Want to see what sits behind that $380 fair value for Onto Innovation? According to FundamentalFlow, the narrative leans heavily on future earnings power, advanced packaging exposure, and a valuation multiple usually reserved for the largest process control players. Curious which specific growth and margin assumptions are doing the heavy lifting in that model? The full narrative lays out the numbers that link today’s price to that higher target.

Result: Fair Value of $380 (UNDERVALUED)

However, Onto Innovation’s story can change quickly if advanced packaging capex slows or if larger process control rivals win key tool qualifications with major fabs.

Another View: Onto Innovation Through The P/E Lens

That $380 fair value narrative for Onto Innovation sits very differently beside current valuation ratios. The stock trades on a P/E of 134.4x, compared with 55.6x for peers, 52x for the US semiconductor industry, and a fair ratio of 39.2x. This suggests the market is already paying a heavy premium that could leave less room for error if expectations slip.

For investors comparing these signals, the key question is whether Onto Innovation’s role in advanced packaging justifies such a stretched multiple, or whether sentiment has already moved too far ahead of fundamentals.

NYSE:ONTO P/E Ratio as at Aug 2026
NYSE:ONTO P/E Ratio as at Aug 2026

Next Steps

With both bullish and cautious voices loud around Onto Innovation, it makes sense to move quickly and review the full picture for yourself. To weigh up the concerns that some investors see alongside the potential rewards others are focused on, start by checking the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Onto Innovation?

Onto Innovation might already be on your radar, but you do not want to miss other opportunities that could round out your portfolio and sharpen your edge.

  • Spot potential value early by scanning 52 high quality undervalued stocks that combine quality fundamentals with prices that analysts expect to be below their assessed worth.
  • Strengthen your income stream by reviewing 7 dividend fortresses that aim to pair higher yields with more durable balance sheets.
  • Protect your downside by focusing on 85 resilient stocks with low risk scores that score better on financial health and business risk than many broader market options.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.